- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
SNMMI: Study Shows Viability of FAPI PET/CT for Predicting Progressive Pulmonary Fibrosis in Lung Disease Patients
For patients with interstitial lung disease, FAPI PET/CT was more effective than 18F-FDG PET/CT at predicting progressive pulmonary fibrosis according to comparative study findings presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
Emerging research suggests that fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) may be more advantageous than 18F-FDG PET/CT for early detection of progressive pulmonary fibrosis (PPF) in patients with interstitial lung disease (ILD).
In the comparative study, presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, researchers reviewed pulmonary function tests and imaging data from 97 patients with ILD who had FAPI PET/CT and 18F-FDG PET/CT.
While both imaging modalities demonstrated an 89 percent specificity rate for predicting PPF, the researchers found that FAPI PET/CT had a significantly higher area under the curve (AUC) than 18F-FDG PET/CT (98 percent vs. 81 percent) and a 33 percent higher sensitivity rate (100 percent vs. 67 percent).
Here one can see 18F-FDG PET/CT and FAPI PET/CT imaging in a 46-year-old man one month after diagnosis of interstitial lung disease (ILD). For this patient, there was an SUVmax (yellow arrow) of 8.3 on FAPI PET/CT in contrast to 4.2 on 18F-FDG PET/CT. (Images courtesy of SNMMI.)
“While 18F-FDG PET/CT can offer some information about ILDs, FAPI PET/CT could provide even more information to physicians, especially regarding progressive pulmonary fibrosis. This could make it a promising diagnostic tool,” noted lead study author Qi Fang, M.D., a resident in the Department of Nuclear Medicine at Guangzhou Medical University in Guangzhou, China.
The researchers noted the whole lung SUVmean (WL-SUVmean) was a key differentiating parameter. Overall, the WL-SUVmean was significantly higher with FAPI PET/CT in comparison to 18F-FDG PET/CT (1.04 vs. 0.82). Patients with PFF demonstrated a higher WL-SUVmean than those without PPF (1.24 vs. 0.73), according to the study authors.
Fang and colleagues suggested the WL-SUVmean could be a “pivotal parameter” with FAPI PET/CT as a key source of metabolic information in patients with ILD.
“These findings underscore the potential utility of FAPI PET/CT as an imaging modality for diagnosing ILD,” said Fang. “In particular, our research shows that patients with high whole-lung SUVmean on FAPI scans tend to manifest progressive pulmonary fibrosis one year later. As such, these patients should be more carefully treated, and anti-fibrosis treatment should begin as early as possible.”
(Editor’s note: For additional content from the SNMMI conference, click here.)
Reference
1. Fang Q, Zhao R, Cui J, et al. Comparative analysis of FDG and FAPI PET/CT imaging in interstitial lung disease: focused on progressive pulmonary fibrosis prediction. Presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 8-11, Toronto, Canada. Available at: https://www.xcdsystem.com/snmmi/program/10OD8Tq/index.cfm?pgid=1579&RunRemoveSessionFilter=1 . Accessed June 8, 2024.
Emerging PET Agent Garners Second FDA Fast Track Designation for Prostate Cancer Imaging
January 24th 2025In addition to an August FDA fast track designation for PSMA PET imaging in patients with suspected metastasis, the radiopharmaceutical 64Cu-SAR-bisPSMA has earned another fast track designation for imaging of biochemical recurrence.
PET Agent Gets FDA Fast Track Designation for Cardiac AL and ATTR Amyloidosis
January 22nd 2025Previously approved for the detection of neuritic beta amyloid plaque, the PET agent (18F)florbetaben is currently being evaluated in a phase 3 multicenter trial for the diagnosis of cardiac amyloidosis.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
